RxDoctor Payments DataLook up a doctor →

Trent Giles, DO

Family Medicine · Nampa, IDNPI 1457738841

Payments from drug & device makers

$7,886in general payments, 2019–2025

Across 436 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$975
  • AstraZeneca$893
  • Novo Nordisk$776
  • Amgen$656
  • Corcept Therapeutics$502
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,886 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$69,772
Medicare patients
151
Services billed
1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide166$179,657
OzempicSemaglutide36$64,569
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$56,067
EliquisApixaban39$44,917
XifaxanRifaximin12$38,220
TrulicityDulaglutide17$37,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$36,504
JardianceEmpagliflozin19$36,163
FarxigaDapagliflozin Propanediol25$32,014
Xigduo XrDapaglifloz Propaned/Metformin35$30,691
Synjardy XrEmpagliflozin/Metformin Hcl26$21,209
Soliqua 100-33Insulin Glargine/Lixisenatide17$15,068
TrulancePlecanatide11$11,898
LinzessLinaclotide19$11,846
Pregabalin110$8,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$351$217,474183 claims
AstraZenecaBreztri Aerosphere, Farxiga$893$88,08190 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$284$64,87557 claims
Novo NordiskOzempic$776$64,56936 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$200$50,11823 claims
PfizerEliquis$1,007$44,91739 claims
GSKTrelegy Ellipta$179$36,50425 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$146$15,06817 claims
AbbVieLinzess$975$11,84619 claims
Johnson & JohnsonXarelto$111$8,45511 claims
BayerKerendia$228$8,20713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.

Other family medicine in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →